Vor Bio completes Phase 3 gMG enrollment, targets topline results in 1H 2027
AI Summary- Vor Bio completed enrollment in the Phase 3 UPSTREAM MG trial of telitacicept.
- $481.6 million in cash and investments was reported as of September 30, 2026.
- Vor Bio plans first-patient dosing for UPSTREAM oMG in the first half of 2027.